CTXR - Company ID 0001506251
The table below shows Citius Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $1.67M | $3.94M | - | - | - | - |
| Cost of revenue | $328.88K | $789.21K | - | - | - | - |
| Gross profit | $1.34M | $3.15M | - | - | - | - |
| R&D | $1.63M | $1.60M | $1.62M | $3.77M | $2.13M | $2.76M |
Citius Pharmaceuticals, Inc. reported annual revenue of $90.00K for fiscal year 2022. That is up 0.0% from $90.00K in fiscal 2021. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $26.39M |
| $5.72M |
| $4.45M |
| $4.79M |
| $5.39M |
| $4.81M |
| Operating income | -$32.19M | -$9.02M | -$8.79M | -$11.26M | -$10.04M | -$10.63M |
| Income tax | -$231.21K | $264.24K | $264.24K | $264.24K | $264.24K | $144.00K |
| Net income | - | - | - | -$11.51M | -$10.28M | -$10.57M |
| EPS (diluted) | -$0.95 | -$0.38 | -$0.80 | -$1.27 | -$1.30 | -$1.57 |